Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:CBMG NASDAQ:DTIL NASDAQ:HARP NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-2.7%$8.41$6.01▼$11.31$1.66B1.132.16 million shs3.12 million shsCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsDTILPrecision BioSciences$4.50-2.4%$4.80$3.61▼$10.64$54.34M1.6172,710 shs61,452 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/AVYGRVoyager Therapeutics$4.21+0.7%$3.49$2.64▼$8.27$231.86M0.9634,025 shs502,628 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-4.35%-5.50%-23.13%-0.13%CBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%DTILPrecision BioSciences0.00%-9.07%-2.12%-11.18%-55.24%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%VYGRVoyager Therapeutics0.00%-1.42%+12.06%+26.28%-33.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.70-2.7%$8.41$6.01▼$11.31$1.66B1.132.16 million shs3.12 million shsCBMGCellular Biomedicine Group$19.68$11.48▼$19.75$384.69M1.35129,776 shs8,375 shsDTILPrecision BioSciences$4.50-2.4%$4.80$3.61▼$10.64$54.34M1.6172,710 shs61,452 shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/AVYGRVoyager Therapeutics$4.21+0.7%$3.49$2.64▼$8.27$231.86M0.9634,025 shs502,628 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals0.00%-4.35%-5.50%-23.13%-0.13%CBMGCellular Biomedicine Group0.00%0.00%0.00%0.00%0.00%DTILPrecision BioSciences0.00%-9.07%-2.12%-11.18%-55.24%HARPHarpoon Therapeutics0.00%0.00%0.00%0.00%0.00%VYGRVoyager Therapeutics0.00%-1.42%+12.06%+26.28%-33.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70116.88% UpsideCBMGCellular Biomedicine Group 0.00N/AN/AN/ADTILPrecision BioSciences 3.00Buy$47.00944.44% UpsideHARPHarpoon Therapeutics 0.00N/AN/AN/AVYGRVoyager Therapeutics 3.13Buy$13.25214.66% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, CBMG, BCRX, VYGR, and HARP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/7/2025VYGRVoyager TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.008/4/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.007/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.006/30/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.006/30/2025BCRXBioCryst PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$16.00 ➝ $18.006/25/2025BCRXBioCryst PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.59N/AN/A($2.30) per share-3.35CBMGCellular Biomedicine Group$340K0.00N/AN/A$2.89 per share0.00DTILPrecision BioSciences$68.70M0.77N/AN/A$6.87 per share0.66HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12VYGRVoyager Therapeutics$42.58M5.48N/AN/A$5.49 per share0.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.59-6.41%N/A-1.78%11/3/2025 (Estimated)CBMGCellular Biomedicine Group-$49.98MN/AN/AN/AN/AN/A-144.80%-61.68%N/ADTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/AVYGRVoyager Therapeutics-$65M-$1.85N/AN/AN/A-253.49%-37.65%-28.89%11/11/2025 (Estimated)Latest DTIL, CBMG, BCRX, VYGR, and HARP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million8/6/2025Q2 2025VYGRVoyager Therapeutics-$0.48-$0.57-$0.09-$0.57$9.50 million$5.20 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/ACBMGCellular Biomedicine GroupN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.252.22CBMGCellular Biomedicine GroupN/A0.470.47DTILPrecision BioSciences0.665.185.18HARPHarpoon TherapeuticsN/A1.891.89VYGRVoyager TherapeuticsN/A5.435.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%CBMGCellular Biomedicine Group21.98%DTILPrecision BioSciences37.99%HARPHarpoon Therapeutics74.01%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals5.10%CBMGCellular Biomedicine Group8.50%DTILPrecision BioSciences4.00%HARPHarpoon Therapeutics17.00%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableCBMGCellular Biomedicine Group21719.48 millionN/AOptionableDTILPrecision BioSciences20011.79 million11.32 millionNo DataHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableVYGRVoyager Therapeutics10055.47 million52.96 millionOptionableDTIL, CBMG, BCRX, VYGR, and HARP HeadlinesRecent News About These CompaniesNuveen LLC Makes New Investment in Voyager Therapeutics, Inc. $VYGRSeptember 8, 2025 | marketbeat.comVoyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comVoyager to Present at Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsAugust 26, 2025 | marketbeat.comVoyager Therapeutics Extends Cash Runway to 2028August 13, 2025 | msn.comTruist Financial Keeps Their Buy Rating on Voyager Therapeutics (VYGR)August 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from OppenheimerAugust 11, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Receives a Buy from Canaccord GenuityAugust 9, 2025 | theglobeandmail.comVoyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comVoyager Reports Second Quarter 2025 Financial and Operating ResultsAugust 6, 2025 | globenewswire.comVoyager 1 and 2: From Earth to Interstellar Space: The Final Frontier AwaitsJuly 21, 2025 | msn.comRead the NASA ‘Voyager Declaration’ Letter of DissentJuly 21, 2025 | nytimes.comMascarene Partners Acquires Voyager TruckingJuly 18, 2025 | finance.yahoo.comMascarene buys US waste services company Voyager TruckingJuly 18, 2025 | realassets.ipe.comRVoyager Therapeutics adds new gene therapy to Alzheimer’s programJuly 18, 2025 | bioworld.comBMascarene to acquire waste services transport firm Voyager Trucking CorporationJuly 18, 2025 | pehub.comLooking Beyond Voyager 1 And 2July 17, 2025 | msn.comRobert Beltran on Star Trek: I “Risked being fired” Because I Didn’t Like What Was Happening in the Last 3 Years of VoyagerJuly 16, 2025 | fandomwire.comFUranus Heat Readings Contradict 40-Year-Old Voyager 2 ResultsJuly 16, 2025 | msn.comVoyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE ApproachJuly 16, 2025 | finanznachrichten.deVoyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE ApproachJuly 16, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDTIL, CBMG, BCRX, VYGR, and HARP Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.70 -0.21 (-2.65%) Closing price 04:00 PM EasternExtended Trading$7.70 0.00 (-0.06%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Cellular Biomedicine Group NASDAQ:CBMGCellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Precision BioSciences NASDAQ:DTIL$4.50 -0.11 (-2.39%) Closing price 04:00 PM EasternExtended Trading$4.64 +0.14 (+3.00%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Harpoon Therapeutics NASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.Voyager Therapeutics NASDAQ:VYGR$4.21 +0.03 (+0.72%) Closing price 04:00 PM EasternExtended Trading$4.17 -0.04 (-0.97%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
